The Health Sciences Authority (HSA) in Singapore has authorised the use of Cue Health ’s molecular Covid-19 test for self-testing.
The Cue Covid-19 test for self-testing was approved by the HSA through its Pandemic Special Access Route (PSAR).
With the authorisation, the test can now be used at home to detect infection in both symptomatic and asymptomatic individuals above two years of age.
Cue Health has already partnered with local company Omnicell to begin immediately supplying the Cue Covid-19 Test in Singapore.
Omnicell regional account director Yoco Ting said: “Testing remains an important component in Singapore’s overall strategy for managing Covid-19.
“With the recent authorisation of the Cue Covid-19 Test via the PSAR, Omnicell is excited to bring forth into Singapore the technological advancement from Cue and further simplify the Covid-19 testing process by now combining the speed of rapid antigen tests with the lab-quality accuracy of PCR tests.
“We will continue to work closely with local authorities and Cue to further the effort in controlling Covid-19 in Singapore.”
Cue Health is a healthcare technology company headquartered in San Diego, California, US.
Last month, the company introduced its direct-to-consumer (DTC) virtual health platform in the US. The move made its molecular Covid-19 test available through the company’s new eCommerce site and in-app shop.
Commenting on the approval in Singapore, Cue co-founder and CEO Ayub Khattak said: “We are excited to bring Cue’s digitally connected, in-home molecular diagnostics platform to Singaporean stakeholders and help provide immediate access to critical health information.
“With Cue, users will be able to make faster and more informed healthcare decisions at a time when it’s needed most.”
In February, Cue received CE mark for its molecular point-of-care Covid-19 test in the European Union (EU).